KIMS
Krishna Institute Of Medical Sciences Limited
Each stock's 10,000-path forecast, rendered as light.
Krishna Institute Of Medical Sciences Limited (KIMS) Stock Analysis & Case Study
Is KIMS a good buy? The data-driven verdict.
Krishna Institute Of Medical Sciences Limited (KIMS) trades at ₹811,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Krishna Institute Of Medical Sciences Limited (KIMS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 163.0× earnings, ROE of 11.3%, a 62% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
KIMS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How KIMS ranks against the 2,373 companies in our screener
- KIMS's market cap of 34,067 Cr ranks in the 89th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- KIMS's book value of ₹56 ranks in the 36th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- KIMS's promoter holding of 32.5% ranks in the 9th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- KIMS's 3-year profit (PAT) growth of -9.0% ranks in the 20th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- KIMS's 3-year revenue growth of 21.0% ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- KIMS's debt-to-equity ratio of 1.89x is lower than 6% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is KIMS overvalued? KIMS P/E vs peers
KIMS trades at 163.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
KIMS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 5.0y of KIMS history (28%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| KIMS 2027 | ₹596 | ₹885 | ₹1,314 | +9% |
| KIMS 2028 | ₹554 | ₹965 | ₹1,679 | +19% |
| KIMS 2029 | ₹529 | ₹1,052 | ₹2,092 | +30% |
| KIMS 2030 | ₹516 | ₹1,148 | ₹2,552 | +42% |
| KIMS 2031 | ₹518 | ₹1,252 | ₹3,026 | +54% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability KIMS goes up, or doubles?
The bull case for KIMS
- A 10,000-path probability model puts a 62% chance the price is higher in a year, with a median target of ₹885 (+9%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,092.
The bear case & risks
- KIMS's P/E of 163.0x is lower than 6% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 14.4× price-to-book means most of the value is intangible/expectations, not assets on the books.
- KIMS's return on equity of 11.3% ranks in the 56th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- KIMS's Piotroski F-Score of 3/8 ranks in the 15th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹529.
KIMS volatility & expected range, how bumpy is the ride?
Over the last 5.0 years KIMS compounded at 28%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹596-₹1,314, the honest backbone behind any single price target.
KIMS price forecast, the full 60-month probability fan
KIMS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds KIMS hits common targets within the simulated horizon?
Full multi-horizon detail on the KIMS price target & forecast page.
KIMS Piotroski F-Score: 3/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. KIMS scores 3/8, weak on the financial-strength checks.
KIMS MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy KIMS with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 30.17% | 3.3× |
| Zerodha | 30.14% | 3.3× |
| Groww | 30.23% | 3.3× |
| Dhan | 30.14% | 3.3× |
| Kotak NeoCHEAPEST | 30.12% | 3.3× |
| Paytm Money | 30.92% | 3.2× |
| Pocketful | 30.51% | 3.3× |
| Fyers | 31.25% | 3.2× |
| Anand Rathi | 30.14% | 3.3× |
| Bajaj Broking | 31.00% | 3.2× |
| Share India | 30.18% | 3.3× |
Compare every broker on the KIMS MTF page.
About Krishna Institute Of Medical Sciences Limited: sector, index & market-cap context
Krishna Institute Of Medical Sciences Limited (KIMS) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹34,067 Cr. See more stocks on our screener.
How the KIMS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Krishna Institute Of Medical Sciences Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
KIMS analysis, FAQs
Is Krishna Institute Of Medical Sciences Limited (KIMS) a good buy?
On the numbers, Krishna Institute Of Medical Sciences Limited (KIMS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 163.0× earnings, ROE of 11.3%, a 62% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is KIMS overvalued or undervalued?
KIMS trades at 163.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the KIMS share price target for 2031?
KIMS's probability-weighted 2031 median target is ₹1,252, with an 80% range of ₹518-₹3,026 (10,000-path Monte-Carlo).
What is the probability KIMS doubles in 5 years?
The modelled probability of KIMS reaching ₹1,622 (2×) within 5 years is 36%.
What is the bull case for KIMS?
A 10,000-path probability model puts a 62% chance the price is higher in a year, with a median target of ₹885 (+9%).
What are the risks in KIMS?
KIMS's P/E of 163.0x is lower than 6% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 14.4× price-to-book means most of the value is intangible/expectations, not assets on the books. KIMS's return on equity of 11.3% ranks in the 56th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.